Lixisenatide
- Generic Name
- Lixisenatide
- Brand Names
- Adlyxin Starter Kit, Lyxumia, Soliqua
- Drug Type
- Biotech
- CAS Number
- 320367-13-3
- Unique Ingredient Identifier
- 74O62BB01U
Overview
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Background
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Indication
Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus. It is also available in combination with insulin glargine for the same indication.
Associated Conditions
- Type 2 Diabetes Mellitus
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.